{"filings":[{"id":106625,"accession_number":"0001104659-26-018582","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Avenue Therapeutics licenses ATX-04 from Duke University for Pompe disease; plans late-stage development","event_type":"other_material","confidence":"high","bullets":["Exclusive worldwide license from Duke for ATX-04 (clenbuterol) to treat Pompe disease as adjunct to ERT.","Upfront payment plus development, regulatory, and commercial milestone payments; tiered low single-digit royalty on net sales.","Prior Duke clinical study showed ATX-04 improved six-minute walk distance, respiratory muscle strength, and reduced glycogen.","Avenue to assume IND and FDA orphan drug designation for Pompe disease; plans late-stage development leveraging existing data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122956,"accession_number":"0001104659-25-125420","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Avenue Therapeutics shareholders elect all six director nominees and ratify KPMG as auditor","event_type":"other","confidence":"high","bullets":["All six director nominees elected: Jay Kranzler, Faith Charles, Neil Herskowitz, Alexandra MacLean, Curtis Oltmans, Lindsay Rosenwald.","Ratification of KPMG LLP as independent auditor for FY 2025 passed with 3,862,335 votes for, 104,651 against.","Annual meeting held December 30, 2025; record date November 25, 2025; 3,183,426 common shares and 250,000 Class A Preferred shares eligible.","Broker non-votes: 0 on director election; all votes cast on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122955,"accession_number":"0001437749-25-035624","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["5.08","8.01"],"status":"ready","headline":"Avenue Therapeutics sets Dec 30, 2025 annual meeting; Nov 28 deadline for proposals","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for December 30, 2025; proxy statement to be filed with SEC.","Shareholder proposals for proxy inclusion under Rule 14a-8 must be received by November 28, 2025.","Director nominations and other non-14a-8 proposals also due by November 28, 2025.","All proposals must be submitted in writing to Corporate Secretary at Bay Harbor Islands address."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122954,"accession_number":"0001437749-25-034243","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"Avenue Therapeutics' subsidiary Baergic Bio acquired by Axsome for up to $82M milestones plus royalties","event_type":"m_and_a","confidence":"high","bullets":["Axsome acquires 100% of Baergic Bio equity for $0.3M upfront; development/regulatory milestones up to $2.5M (first indication) and $1.5M per subsequent indication.","Sales-based milestones up to $79M; tiered mid-to-high single digit royalty on global net sales of AXS-17 (formerly BAER-101).","Avenue expects to receive ~74% of all future payments and royalties.","Axsome receives worldwide rights to BAER-101 (GABA A PAM) to be evaluated for epilepsy.","CEO granted 443,578 restricted shares; CFO granted 266,147 restricted shares, fully vesting upon closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157238,"accession_number":"0001104659-25-042570","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["1.01","1.02","2.01","9.01"],"status":"ready","headline":"Avenue Therapeutics terminates AJ201 license; gets $2M cash, up to $24M milestones, 1.75% royalty","event_type":"other_material","confidence":"high","bullets":["License terminated; all AJ201 rights and assets transferred back to AnnJi; mutual releases and dismissal of disputes.","Avenue to receive $2M total within 90 days: $1M due in 30 days, $1M due in 90 days.","Potential future payments: up to $5M development milestones, up to $17M commercial milestones, 1.75% royalty on net sales.","Avenue repurchases 14,777 shares from AnnJi for $1.00 aggregate and pays $0.2M for AnnJi legal expenses.","48-month non-compete for competing products in US, Canada, EU, UK, and Israel after termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175610,"accession_number":"0001104659-25-024505","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq to delist Avenue Therapeutics on March 19; stock to trade on OTC Markets","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Company it will delist common stock effective at open on March 19, 2025.","Delisting due to failure to maintain minimum $2.5M stockholders' equity per Nasdaq Rule 5550(b)(1).","Company failed to meet conditions of Panel exception requiring disclosure of equity-increasing transactions by March 14.","Common stock (ATXI) expected to begin trading on OTC Markets on March 19, 2025.","Company will continue filing periodic reports with SEC but warns of uncertain trading liquidity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175609,"accession_number":"0001437749-25-006685","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nasdaq grants Avenue Therapeutics continued listing exception; AnnJi seeks to terminate AJ201 license","event_type":"other_material","confidence":"high","bullets":["Nasdaq Panel granted continued listing subject to: public disclosure by Mar 14, fundraising update by Mar 14, AJ201 trial results by Apr 15.","AnnJi sent termination notice alleging material breaches of AJ201 license; Avenue believes claims are meritless and will contest.","Avenue filed emergency arbitration to block AnnJi from unblinding clinical data in a way that would exhaust irreplaceable samples.","Company must still regain compliance with stockholders' equity requirement; no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}